Full-Time

Scientist – LCMS

Posted on 3/3/2026

BioAgilytix

BioAgilytix

501-1,000 employees

Global bioanalytical testing for drug development

No salary listed

Melbourne VIC, Australia

In Person

Applicants must be Australian or NZ residents with valid Australian work rights.

Category
Biology & Biotech (2)
,
Requirements
  • BSc in Chemistry or related discipline plus at least 5 years' experience (Essential)
  • Experience in medical laboratory techniques for the role required (Essential)
  • Excellent organisational and writing skills (Essential)
  • Ability to work as part of a team (Essential)
  • Experience in method development and validation of HPLC methods (Essential)
  • Experience in method development and validation of LCMS and LCMS/MS methods (Essential)
  • Experience in handling clinical samples and their analysis by bioanalytical methods (Essential)
Responsibilities
  • Ensure the safe and efficient conduct of laboratory activities
  • Ensure compliance to relevant internal processes and statutory requirements
  • Maintain high levels of communication with colleagues and productive relationships with service providers and other partners
  • Adhere to ISO/IEC 17025, OECD Principles of GLP, GCLP/GCP Principles
  • Adhere to 360biolabs’ Quality Management System, and other requirements as per NATA Accreditation and regulatory guidelines
  • Order and maintain supplies for the laboratories
  • Obtain quotes for relevant supplies
  • Ensure laboratory equipment is cleaned, maintained and calibrated as required
  • Ensure good housekeeping in the laboratory
  • Conduct development and validation experiments for bioanalytical methods and assays, including LCMS, LCMS/MS, and HPLC for use in human and animal trials supported by 360biolabs
  • Perform assays for samples collected from research projects, preclinical studies and clinical trials.
  • Assist in the preparation and review of policies, SOPs, systems and procedures to assure the quality and integrity of service offerings at 360biolabs
  • Maintain records (LIMS, database and experiment records) consistent with relevant standards and industry expectations
  • Perform data analysis, presentation and interpretation where appropriate
  • Assist in the production of both internal reports and reports for clients
  • Participate in and actively contribute to technical discussions with clients
  • Attend meetings and training associated with the bioanalytical chemistry work of 360biolabs
  • Participate in training activities and attendance at seminars in the field of expertise
Desired Qualifications
  • PhD in Chemistry or Analytical Chemistry or equivalent experience
  • Experience in testing drugs, small molecules, metabolites, peptides and/or proteins, preferably in an industry or contract research environment
  • Experience in the conduct of early phase clinical trials
  • Experience working in a quality-controlled environment preferably an accredited facility following ISO/IEC 17025, GLP or similar
  • High motivation and enthusiasm for medical research and the progression of therapeutics and vaccines

BioAgilytix is a global bioanalytical laboratory that provides testing services for pharmaceutical, biotechnology, and agricultural biotech companies, with a notable presence in Hamburg, Europe. It specializes in large-molecule studies and runs assays such as pharmacokinetics, pharmacodynamics, cell-based tests, and immunogenicity to measure how drugs behave in the body and assess safety and efficacy. The company offers customizable, service-based testing that supports drug development from research through regulatory approval, including COVID-19 testing packages. Its differentiators are its global reach, deep expertise in large-molecule workflows, and a flexible model that partners with clients on a project basis. Its goal is to deliver precise, validated bioanalytical data that helps clients develop and bring new therapies to market.

Company Size

501-1,000

Company Stage

Growth Equity (Venture Capital)

Total Funding

$30.1M

Headquarters

Durham, North Carolina

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Gene therapy market expansion as anti-AAV assay addresses rare disease diagnostics.
  • European market growth through Hamburg lab qPCR expansion and leadership hires.
  • Strategic partnerships with BBI Solutions and A3P Biomedical diversify revenue streams.

What critics are saying

  • Cancelled $61.5M Durham expansion forfeits 878 jobs, damaging talent acquisition capacity.
  • Charles River and Labcorp undercut pricing via integrated CRO scale advantages.
  • Eurofins AI-optimized assays deliver 40% faster turnaround, threatening biotech client retention.

What makes BioAgilytix unique

  • FDA Breakthrough Device Designation for anti-AAV antibody assay supporting gene therapy.
  • Global laboratory network across US, Australia, Germany enabling early-phase to market authorization.
  • Specialized expertise in large molecule bioanalysis, immunogenicity, and cell-based assays.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Company Match

Parental Leave

Employee Referral Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

18%
The Associated Press
Feb 10th, 2026
BioAgilytix receives FDA breakthrough device designation for anti-AAV antibody assay supporting gene therapy

BioAgilytix Labs has received FDA Breakthrough Device Designation for its anti-AAV antibody assay supporting Lexeo Therapeutics' gene therapy programme for Friedreich ataxia cardiomyopathy, a rare progressive disorder affecting approximately 15,000 people worldwide. The plate-based MSD anti-adeno-associated virus serotype rh.10 total antibody assay enables precise patient selection and monitoring for gene therapy programmes. The FDA's Breakthrough Device Designation expedites development and review of novel medical devices treating life-threatening or irreversibly debilitating conditions. BioAgilytix is among a limited number of contract research organisations to receive breakthrough designation for a diagnostic assay supporting an investigational device exemption. The Durham, North Carolina-based company operates laboratories across the US, Australia and Germany, providing bioanalytical testing services for pharmaceutical and biotechnology organisations.

Rapid Test Methods Ltd
Jun 18th, 2024
BBI and BioAgilytix Partner to Streamline and Simplify Bioanalytical Testing

BBI Solutions OEM Limited (BBI), a trusted expert provider of end-to-end solutions for the development of high-performance assays, has signed a partnership agreement with BioAgilytix, a leading global bioanalytical laboratory.

The Business Journals
Mar 26th, 2024
Durham firm cancels deal that promised 878 jobs

BioAgilytix in 2020 picked the Triangle over competing sites in Massachusetts for a $61.5 million expansion that was expected to add 878 local jobs.

360Dx
Sep 13th, 2023
A3P Biomedical, BioAgilytix Partner to Bring Prostate Cancer Test to US

NEW YORK - Swedish diagnostics firm A3P Biomedical announced on Wednesday that it has partnered with BioAgilytix to bring A3P's prostate cancer test to the US as a laboratory-developed test.

A3P Biomedical
Sep 13th, 2023
A3P Biomedical and BioAgilytix enter partnership for Stockholm3 in the USA

Recognizing the critical need for improved prostate cancer diagnostics, A3P Biomedical and BioAgilytix have joined forces to introduce Stockholm3 as a novel LDT in the US market.

INACTIVE